M. Roach, V. Weinberg, and H. Sandler, Staging for prostate cancer, Cancer, vol.59, issue.2, pp.213-220, 2007.
DOI : 10.1002/cncr.22403

D. Kuban, A. Mahdi, and P. Schellhammer, Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer, International Journal of Radiation Oncology*Biology*Physics, vol.32, issue.2, pp.307-316, 1995.
DOI : 10.1016/0360-3016(95)00137-N

W. Shipley, H. Thames, and H. Sandler, Radiation Therapy for Clinically Localized Prostate Cancer, JAMA, vol.281, issue.17, pp.1598-1604, 1999.
DOI : 10.1001/jama.281.17.1598

G. Zagars, A. Pollack, and V. Kavadi, Prostate-specific antigen and radiation therapy for clinically localized prostate cancer, International Journal of Radiation Oncology*Biology*Physics, vol.32, issue.2, pp.293-306, 1995.
DOI : 10.1016/0360-3016(95)00077-C

L. Kestin, F. Vicini, and E. Ziaja, Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy, Cancer, vol.72, issue.8, pp.1557-1566, 1999.
DOI : 10.1002/(SICI)1097-0142(19991015)86:8<1557::AID-CNCR24>3.0.CO;2-2

G. Zagars, V. Eschenbach, and A. , Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy, Cancer, vol.68, issue.2, pp.538-548, 1993.
DOI : 10.1002/1097-0142(19930715)72:2<538::AID-CNCR2820720234>3.0.CO;2-S

W. Lee, G. Hanks, and A. Hanlon, Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations., Journal of Clinical Oncology, vol.15, issue.1, pp.230-238, 1997.
DOI : 10.1200/JCO.1997.15.1.230

H. Thames, D. Kuban, and L. Levy, Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995, International Journal of Radiation Oncology*Biology*Physics, vol.57, issue.4, pp.929-943, 2003.
DOI : 10.1016/S0360-3016(03)00631-X

A. Pollack, G. Zagars, and V. Kavadi, Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer, Cancer, vol.45, issue.2, pp.670-678, 1994.
DOI : 10.1002/1097-0142(19940715)74:2<670::AID-CNCR2820740220>3.0.CO;2-8

C. Sartor, M. Strawderman, and X. Lin, Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.38, issue.5, pp.941-947, 1997.
DOI : 10.1016/S0360-3016(97)00082-5

D. Amico, A. Moul, J. Carroll, and P. , PROSTATE SPECIFIC ANTIGEN DOUBLING TIME AS A SURROGATE END POINT FOR PROSTATE CANCER SPECIFIC MORTALITY FOLLOWING RADICAL PROSTATECTOMY OR RADIATION THERAPY, The Journal of Urology, vol.172, issue.5, pp.42-46, 2004.
DOI : 10.1097/01.ju.0000141845.99899.12

G. Duchesne, J. Millar, and V. Moraga, What to do for prostate cancer patients with a rising PSA????a survey of Australian practice, International Journal of Radiation Oncology*Biology*Physics, vol.55, issue.4, pp.986-991, 2003.
DOI : 10.1016/S0360-3016(02)04213-X

M. Roach, G. Hanks, H. Thames, and . Jr, Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference, International Journal of Radiation Oncology*Biology*Physics, vol.65, issue.4, pp.965-974, 2006.
DOI : 10.1016/j.ijrobp.2006.04.029

I. Thompson, D. Ankerst, and C. Chi, Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower, JAMA, vol.294, issue.1, pp.66-70, 2005.
DOI : 10.1001/jama.294.1.66

J. Taylor, M. Yu, and H. Sandler, Individualized Predictions of Disease Progression Following Radiation Therapy for Prostate Cancer, Journal of Clinical Oncology, vol.23, issue.4, pp.816-825, 2005.
DOI : 10.1200/JCO.2005.12.156

J. Michalski, K. Winter, and J. Purdy, Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V, International Journal of Radiation Oncology*Biology*Physics, vol.62, issue.3, pp.706-713, 2005.
DOI : 10.1016/j.ijrobp.2004.11.028

M. Roach, K. Winter, and J. Michalski, Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study, International Journal of Radiation Oncology*Biology*Physics, vol.60, issue.5, pp.1351-1356, 2004.
DOI : 10.1016/j.ijrobp.2004.05.026

S. Williams, G. Duchesne, and J. Millar, Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer, International Journal of Radiation Oncology*Biology*Physics, vol.60, issue.4, pp.1082-1087, 2004.
DOI : 10.1016/j.ijrobp.2004.04.048

S. Williams, J. Taylor, and N. Liu, Use of Individual Fraction Size Data from 3756 Patients to Directly Determine the ??/?? Ratio of Prostate Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.68, issue.1, pp.24-33, 2007.
DOI : 10.1016/j.ijrobp.2006.12.036

N. Laird and J. Ware, Random-Effects Models for Longitudinal Data, Biometrics, vol.38, issue.4, pp.963-974, 1982.
DOI : 10.2307/2529876

A. Tsiatis, D. Gruttola, V. Wulfsohn, and M. , Modelling the relationship of survival to longitudinal data measured with error. Application to survival and SC4 counts in patients with AIDS

M. Roach, V. Weinberg, and P. Mclaughlin, Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate, Urology, vol.61, issue.4, pp.730-735, 2003.
DOI : 10.1016/S0090-4295(02)02425-1

A. Hanlon, H. Diratzouian, and G. Hanks, Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer, International Journal of Radiation Oncology*Biology*Physics, vol.53, issue.2, pp.297-303, 2002.
DOI : 10.1016/S0360-3016(02)02717-7

A. Lee, L. Levy, and R. Cheung, Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy, International Journal of Radiation Oncology*Biology*Physics, vol.63, issue.2, pp.456-62, 2005.
DOI : 10.1016/j.ijrobp.2005.03.008

W. Kwan, T. Pickles, and G. Duncan, PSA failure and the risk of death in prostate cancer patients treated with radiotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.60, issue.4, pp.1040-1046, 2004.
DOI : 10.1016/j.ijrobp.2004.03.044

P. Zhou, M. Chen, and D. Mcleod, Predictors of Prostate Cancer???Specific Mortality After Radical Prostatectomy or Radiation Therapy, Journal of Clinical Oncology, vol.23, issue.28, pp.6992-6998, 2005.
DOI : 10.1200/JCO.2005.01.2906

H. Thames, D. Kuban, and M. Desilvio, Increasing external beam dose for T1???T2 prostate cancer: Effect on risk groups, International Journal of Radiation Oncology*Biology*Physics, vol.65, issue.4, pp.975-981, 2006.
DOI : 10.1016/j.ijrobp.2006.02.043

G. Hanks, A. Hanlon, and B. Epstein, Dose response in prostate cancer with 8???12 years??? follow-up, International Journal of Radiation Oncology*Biology*Physics, vol.54, issue.2, pp.427-435, 2002.
DOI : 10.1016/S0360-3016(02)02954-1

C. C. Parker, M. Gospodarowicz, and P. Warde, Does age influence the behaviour of localized prostate cancer?, BJU International, vol.48, issue.Suppl 1, pp.629-666, 2001.
DOI : 10.1046/j.1464-410x.2001.02141.x

T. Pickles, Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy, International Journal of Radiation Oncology*Biology*Physics, vol.64, issue.5, pp.1355-1359, 2006.
DOI : 10.1016/j.ijrobp.2005.10.008